Short answer
Trevi Therapeutics, Inc. (TRVI) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$12M
- +10.9% YoY · +4.1% QoQ
- EPS (diluted)
- −$0.08
- +38.5% YoY · +11.1% QoQ
Source: XBRL data from the Trevi Therapeutics, Inc. (TRVI) Q3 2025 10-Q on SEC EDGAR. USD.
Trevi Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged from $0 YoY; no product sales since inception
- Net loss $11.8M vs $13.2M YoY; operating loss $13.9M vs $14.1M
- R&D expenses $10.1M vs $11.2M; G&A expenses $3.8M vs $2.9M
- Cash, equivalents and marketable securities $194.9M at September 30, 2025; funding expected for at least 12 months
- June 2025 offering generated $115.1M gross proceeds; substantial additional funding expected for development programs
Risk Factors
- Cash, equivalents and marketable securities $194.9M; funding expected into 2028, subject to FDA study-design alignment
- Additional capital required for Haduvio development through regulatory approval, with no committed external funding source
- Haduvio remains Trevi’s sole product candidate, concentrating development and commercialization risk in one program
- Planned Phase 3 IPF program and trials in non-IPF ILD and RCC increase near-term clinical execution and enrollment risk
- FDA, EMA and MHRA approvals remain uncertain because Haduvio has not demonstrated efficacy in chronic-cough indications
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Trevi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.